USMI to Debut the Canady Robotic AI Surgical System at the First Global Surgical Oncology Summit Jerusalem, Israel January 2024

The Jerome Canady Research Institute for Advanced and Biological Technological Sciences (JCRI-ABTS) and US Medical Innovations, LLC (USMI) are pleased to announce today a ground-breaking achievement in surgical and robotic technology. The Canady Robotic AI Surgical System is the world’s first…

Read MoreUSMI to Debut the Canady Robotic AI Surgical System at the First Global Surgical Oncology Summit Jerusalem, Israel January 2024

Global Cardiac Holter Monitor Market Size, Trends & Forecast Report 2023-2030 Featuring General Electric, NIHON KOHDEN, Hill-Rom, OSI Systems, Boston Scientific, Koninklijke Philips, and Medtronic – ResearchAndMarkets.com

The “Cardiac Holter Monitor Market, Size, Global Forecast 2023-2030, Industry Trends, Share, Growth, Insight, Impact of Inflation, Company Analysis” report has been added to ResearchAndMarkets.com’s offering. Global Cardiac Holter Monitor Market is projected to reach US$ 713.5 Million in 2030, growing at a CAGR…

Read MoreGlobal Cardiac Holter Monitor Market Size, Trends & Forecast Report 2023-2030 Featuring General Electric, NIHON KOHDEN, Hill-Rom, OSI Systems, Boston Scientific, Koninklijke Philips, and Medtronic – ResearchAndMarkets.com

Kestra Medical Technologies Offers Electrophysiology and Cardiology Clinicians Opportunity to Wear ASSURE WCD System at #HRX2023 Conference

Kestra Medical Technologies is launching the ASSURE Clinician Experience (ACE), a program that lets electrophysiology and cardiology professionals wear and simulate use of the ASSURE® Wearable Cardioverter Defibrillator (WCD) system at The Heart Rhythm Society #HRX2023 global health and technology conference, September 21-23,…

Read MoreKestra Medical Technologies Offers Electrophysiology and Cardiology Clinicians Opportunity to Wear ASSURE WCD System at #HRX2023 Conference

Pfizer Broadens Portfolio of Respiratory Vaccines Recommended by CDC Advisory Committee with ABRYSVO™ for RSV

Pfizer Inc. (NYSE: PFE) shared today it has broadened its portfolio of respiratory vaccines recommended by the U.S. Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) following a favorable vote for ABRYSVO™ [Respiratory Syncytial Virus…

Read MorePfizer Broadens Portfolio of Respiratory Vaccines Recommended by CDC Advisory Committee with ABRYSVO™ for RSV

CORRECTING and REPLACING Surgery Center is First in Southern California to Adopt New Wireless Technology for Arthroscopy

Headline of release should read: Surgery Center is First in Southern California to Adopt New Wireless Technology for Arthroscopy (instead of Santa Barbara Surgery Center is First in Southern California to Adopt New Wireless Technology for Arthroscopy) of release issued…

Read MoreCORRECTING and REPLACING Surgery Center is First in Southern California to Adopt New Wireless Technology for Arthroscopy

Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference

Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a discussion with Albert Bourla, Chairman and Chief Executive Officer, at the 2023 Cantor Global Healthcare Conference on Tuesday, September 26, 2023…

Read MorePfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference

European Commission Approves Pfizer’s LITFULO™ for Adolescents and Adults With Severe Alopecia Areata

Pfizer Inc. (NYSE: PFE) today announced that the European Commission (EC) has granted marketing authorization for LITFULO™ (ritlecitinib) to treat adults and adolescents 12 years of age and older with severe alopecia areata. LITFULO, a once-daily oral capsule, is the…

Read MoreEuropean Commission Approves Pfizer’s LITFULO™ for Adolescents and Adults With Severe Alopecia Areata

FDA Accepts for Priority Review Merck’s Supplemental New Drug Application for WELIREG® (belzutifan) in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma (RCC)

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) has accepted and granted priority review for a supplemental new drug application (sNDA) seeking approval for WELIREG, Merck’s…

Read MoreFDA Accepts for Priority Review Merck’s Supplemental New Drug Application for WELIREG® (belzutifan) in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma (RCC)

BrainScope Receives Investment from the Alzheimer’s Drug Discovery Foundation for Alzheimer’s Prediction Biomarker

Brain diagnostics innovator BrainScope announced today a new investment from the Alzheimer’s Drug Discovery Foundation (ADDF) in BrainScope’s current Series B equity financing round. This investment supports the ongoing development of a new Artificial Intelligence / Machine Learning derived brain-activity based biomarker…

Read MoreBrainScope Receives Investment from the Alzheimer’s Drug Discovery Foundation for Alzheimer’s Prediction Biomarker

Stryker Launches PROstep® MIS Lapidus, a New Minimally Invasive Surgical Option for Treating Patients with Bunions

Stryker (NYSE: SYK), one of the world’s leading medical technology companies, announced the launch of PROstep® MIS Lapidus, a new internal fixation system intended for treating bunions using a minimally invasive surgical reduction of hallux valgus deformity and subsequent fusion of…

Read MoreStryker Launches PROstep® MIS Lapidus, a New Minimally Invasive Surgical Option for Treating Patients with Bunions